Literature DB >> 32776055

Cytotoxic and antitumor peptides as novel chemotherapeutics.

Xin Luan1, Ye Wu, Yi-Wen Shen, Hong Zhang, Yu-Dong Zhou, Hong-Zhuan Chen, Dale G Nagle, Wei-Dong Zhang.   

Abstract

Covering: up to 2020Treatment resistance and drug-induced refractory malignancies pose significant challenges for current chemotherapy drugs. There have been increasing research efforts aimed at developing novel chemotherapeutics, especially from natural products and related derivatives. Natural cytotoxic peptides, an emerging source of chemotherapeutics, have exhibited the advantage of overcoming drug resistance and displayed broad-spectrum antitumor activities in the clinic. This highlight examines the increasingly popular cytotoxic peptides from isolated natural products. In-depth review of several peptides provides examples for how this novel strategy can lead to the improved anti-tumor effects. The mechanisms and current application of representative natural cytotoxic peptides (NCPs) have also been discussed, with a particular focus on future directions for interdisciplinary research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32776055      PMCID: PMC9414093          DOI: 10.1039/d0np00019a

Source DB:  PubMed          Journal:  Nat Prod Rep        ISSN: 0265-0568            Impact factor:   15.111


  87 in total

Review 1.  Targeting and extending the eukaryotic druggable genome with natural products: cytoskeletal targets of natural products.

Authors:  April L Risinger; Lin Du
Journal:  Nat Prod Rep       Date:  2019-11-25       Impact factor: 13.423

Review 2.  Cyclic peptide natural products chart the frontier of oral bioavailability in the pursuit of undruggable targets.

Authors:  Matthew R Naylor; Andrew T Bockus; Maria-Jesus Blanco; R Scott Lokey
Journal:  Curr Opin Chem Biol       Date:  2017-05-29       Impact factor: 8.822

3.  Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1.

Authors:  H Luesch; R E Moore; V J Paul; S L Mooberry; T H Corbett
Journal:  J Nat Prod       Date:  2001-07       Impact factor: 4.050

Review 4.  Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy.

Authors:  Islam Rady; Imtiaz A Siddiqui; Mohamad Rady; Hasan Mukhtar
Journal:  Cancer Lett       Date:  2017-05-20       Impact factor: 8.679

Review 5.  Phospholipids in animal eukaryotic membranes: transverse asymmetry and movement.

Authors:  A Zachowski
Journal:  Biochem J       Date:  1993-08-15       Impact factor: 3.857

6.  LTX-315: a first-in-class oncolytic peptide that reprograms the tumor microenvironment.

Authors:  Baldur Sveinbjørnsson; Ketil Andre Camilio; Bengt Erik Haug; Øystein Rekdal
Journal:  Future Med Chem       Date:  2017-05-11       Impact factor: 3.808

7.  Tachyplesin activates the classic complement pathway to kill tumor cells.

Authors:  Jinguo Chen; Xue-Ming Xu; Charles B Underhill; Shanmin Yang; Luping Wang; Yixin Chen; Shuigen Hong; Karen Creswell; Lurong Zhang
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

8.  Experimental local therapy of human melanoma with lytic magainin peptides.

Authors:  P W Soballe; W L Maloy; M L Myrga; L S Jacob; M Herlyn
Journal:  Int J Cancer       Date:  1995-01-17       Impact factor: 7.396

9.  Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserine.

Authors:  Sabrina Riedl; Regina Leber; Beate Rinner; Helmut Schaider; Karl Lohner; Dagmar Zweytick
Journal:  Biochim Biophys Acta       Date:  2015-08-01

Review 10.  Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets.

Authors:  Renato B Pereira; Nikolai M Evdokimov; Florence Lefranc; Patrícia Valentão; Alexander Kornienko; David M Pereira; Paula B Andrade; Nelson G M Gomes
Journal:  Mar Drugs       Date:  2019-06-02       Impact factor: 5.118

View more
  1 in total

Review 1.  Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment.

Authors:  Anita Bakrania; Gang Zheng; Mamatha Bhat
Journal:  Pharmaceutics       Date:  2021-12-25       Impact factor: 6.321

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.